Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2018 to 2023

  • ID: 4580474
  • Report
  • Region: Global
  • 284 Pages
  • Howe Sound Research
1 of 5
Search for Alternatives to Antibiotics Creates New Global Technology Race

FEATURED COMPANIES

  • ABAC Therapeutics
  • AstraZeneca
  • Deinobiotics/Deinove
  • MaaT Pharma
  • Novartis
  • Spero Therapeutics
  • MORE

Antimicrobial Resistance is creating new kinds of infections and “superbugs” that are resistant to current antibiotic medicines.  New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. 

We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play.

This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ABAC Therapeutics
  • AstraZeneca
  • Deinobiotics/Deinove
  • MaaT Pharma
  • Novartis
  • Spero Therapeutics
  • MORE

1. Introduction and Market Definition 
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics
1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market
2.1 Market Players – Roles & Impacts
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic
2.1.3 Contract Research and Manufacturing
2.1.4 In Vitro Diagnostics Industry
2.1.5 Drug Marketing Companies
2.1.6 Biotechnology Companies
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance
2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes
2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP) 3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Therapeutic Technology Development Opportunities
3.2.1 Using Viruses Against Bacteria
3.2.2 Hydrolytic Enzymes Join the Fight
3.2.3 Antibodies
3.2.4 Vaccines
3.2.5 Probiotic Technology
3.2.6 Peptides vs. Pathogens
3.2.7 Mining Obsolete Science
3.2.8 CRISPR Antibiotics
3.3. Antibiotic Resistance Recent Developments
3.3.1 Recent Developments – Importance and How to Use This Section
3.3.2 Importance of These Developments
3.3.3 How to Use This Section
3.3.72   Amicrobe, Inc., patents AMR Gel
3.3.73 MICRONEEDLE PATCH TO COMBAT ANTIMICROBIAL RESISTANCE
3.3.74  Antimicrobial peptides find application medium
3.3.75  Antibiotic shortages fuelling antimicrobial resistance
3.3.4 Superbug Arises in China
3.3.5 Bruker Announces Acquisition of MERLIN
3.3.6 Antibiotics Firms Cempra, Melinta Therapeutics Agree to Merger
3.3.7 Antibiotic Alternative Micreos wins Most Impactful Innovation
3.3.8 Roche kicks antibiotic development into Warp Drive
3.3.9 Iterum Gains Support for Sulopenem Development
3.3.10 VenatoRx Pharmaceuticals Raises $42 Million Series B
3.3.11 Wockhardt Receives Approval for Phase III Trial
3.3.12 Phagelux, Inc. Announces Collaboration with Johnson & Johnson
3.3.13 bioMérieux, Inc. and McKesson Medical-Surgical Announce Distribution Alliance
3.3.14 AstraZeneca to sell antibiotics branch to Pfizer
3.3.15 Microbiotix and AMR Centre Announce Co-Development Agreement
3.3.16 Hennepin Life Sciences Presents Pre-Clinical Data
3.3.17 bioMérieux receives FDA clearance for expanded pathogen identification capability
3.18 Sequoia Sciences Receives FDA Fast Track Designation
3.19 Forge Therapeutics Presents New Efficacy Data
3.20 Acquisition Strategy Fills Out Roche's Pipeline
3.21 Alopexx completes trial of broad-spectrum anti-microbial vaccine
3.22 Integrated Biotherapeutics Partners with CARB-X for MRSA Vaccine
3.23 BD Molecular Test for Infectious Diarrhea Cleared
3.24 Fusion Genomics Developing All Pathogens Diagnostic

4. Key Biotechnology Companies and Their Technology
4.2 Therapeutics
4.2.1 The Medicines Company
4.2.2 Melinta Therapeutics
4.2.3 Arsanis
4.2.4 Phage Technologies S.A
4.2.5 Westway Health
4.2.6 Tetraphase Pharmaceuticals
4.2.7 BioVersys GmbH
4.2.8  Nabriva Therapeutics
4.2.9 Macrolide Pharmaceuticals
4.2.10 Nemesis Bioscience
4.2.11 C3J Therapeutics, Inc.
4.2.12 EpiBiome
4.2.13 discuva
4.2.14 SmartPhage
4.2.15 AmpliPhi Biosciences
4.2.16 Pherecydes Pharma
4.2.17 Micreos
4.2.18 Procarta Biosystems
4.2.19 Lumavita
4.2.20 Madam Therapeutics
4.2.21 Priaxon
4.2.22 Biolytx Pharmaceuticals
4.2.23 AntibioTx
4.2.24 Xellia Pharmaceuticals
4.2.25  Paratek Pharmaceuticals
4.2.26 Synereca Pharmaceuticals
4.2.27 Allecra Therapeutics
4.2.28 Fixed Phage
4.2.29 Enanta Pharmaceuticals, Inc.
4.2.30 Demuris
4.2.31 Prommune
4.2.32 Biosergen
4.2.33 Innovation Pharmaceuticals
4.2.34 Aviragen Therapeutics
4.2.35 Achillion Pharmaceuticals
4.2.36 ImmunNovative Developments, S.L.
4.2.37 Achaogen, Inc.
4.2.38 SelectX Pharmaceuticals, Inc.
4.2.39 TaiGen Biotechnology Co., Ltd.
4.2.40 Theravance Biopharma
4.2.41 Abbvie
4.2.42 KYORIN Pharmaceutical Co.,Ltd.
4.2.43 Iterum Therapeutics Limited
4.2.44 Forge Therapeutics
4.2.45 Alopexx Vaccine LLC
4.2.46 Integrated Biotherapeutics
4.2.47 Hennepin Life Sciences
4.2.48 Fedora Pharmaceuticals Inc.
4.2.49  Contrafect Corporation
4.2.50 Basilea Pharmaceutica Ltd.
4.2.51 AiCuris
4.2.52 RedHill Biopharma
4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
4.2.54 ABAC Therapeutics
4.2.55 Alaxia SAS
4.2.56 Antabio S.A.S
4.2.57 Auspherix Ltd
4.2.58 BioFilm Pharma
4.2.59 Centauri Therapeutics Ltd
4.2.60 Combioxin SA
4.2.61 Da Volterra
4.2.62 Debiopharm International SA
4.2.63 Deinobiotics/Deinove
4.2.64 Destiny Pharma plc
4.2.65 Eligo Bioscience
4.2.66 Helperby Therapeutics Ltd
4.2.67 Karveel Pharmaceuticals
4.2.68 MaaT Pharma
4.2.69 Motif BioSciences, Inc / Motif Bio PLC
4.2.70 Mutabilis SAS
4.2.71 Neem Biotech Ltd
4.2.72 Northern Antibiotics Oy (Ltd)
4.2.73 Nosopharm
4.2.74 NovaBiotics Ltd
4.2.75 Phico Therapeutics Ltd
4.2.76 Polyphor Ltd
4.2.77 QureTech Bio AB
4.2.78 SetLance srl
4.2.79 Ultupharma AB
4.2.80 Vaxdyn
4.2.81 Vibiosphen
4.2.82 Bioaster
4.2.83 Vivexia
4.2.85 KBP Biosciences
4.2.86 Absynth Biologics
4.2.87 Spero Therapeutics
4.2.88 Merck
4.2.89 Symphogen
4.2.90 Warp Drive Bio
4.2.91 Johnson & Johnson (Janssen)
4.2.92 Pfizer
4.2.93 Allergan
4.2.95 Novartis
4.2.97 AstraZeneca
4.2.100 Cipla
4.2.101 DSM Sinochem Pharmaceuticals
4.2.102 Wockhardt Ltd.
4.2.103 VenatoRx Pharmaceuticals
4.2.104 MicuRx
4.2.105 Entasis Therapeutics
4.2.106 Merlion Pharmaceuticals
4.3 The Therapeutics Race – Summary of Companies Research Areas

5.  Country Market Sizes – North America 2017 to 2023
5.1 United States of America 2017 to 2023
5.1.1 USA by Pathogen
5.1.2 USA by Technology Opportunity
5.2 Canada 2017 to 2023
5.1.1 Canada by Pathogen 5.1.2 Canada by Technology Opportunity

6. Country Markets – Europe 2017 to 2023
6.1 France 2017 to 2023
6.1.1 France by Pathogen
6.1.2 France by Technology Opportunity
6.2 Germany 2017 to 2023
6.2.1 Germany by Pathogen
6.2.2 Germany by Technology Opportunity
6.3 United Kingdom 2017 to 2023
6.3.1 United Kingdom by Pathogen
6.3.2 United Kingdom by Technology Opportunity
6.4 Spain 2017 to 2023
6.4.1 Spain by Pathogen
6.4.2 Spain by Technology Opportunity
6.5 Italy 2017 to 2023
6.5.1 Italy by Pathogen
6.5.2 Italy by Technology Opportunity
6.6 Russia 2017 to 2023
6.6.1 Russia by Pathogen
6.6.2 Russia by Technology Opportunity
6.7 Remainder of Europe and Former USSR 2017 to 2023
6.7.1 Remainder of Europe and Former USSR by Pathogen
6.7.2 Remainder of Europe and Former USSR by Technology Opportunity

7. Country Markets – Asia Pacific 2017 to 2023
7.1 China 2017 to 2023
7.1.1 China by Pathogen
7.1.2 China by Technology Opportunity
7.2 Japan 2017 to 2023
7.2.1 Japan by Pathogen
7.2.2 Japan by Technology Opportunity
7.3 South Korea 2017 to 2023
7.3.1 South Korea by Pathogen
7.3.2 South Korea by Technology Opportunity
7.4 India 2017 to 2023
7.4.1 India by Pathogen
7.4.2 India by Technology Opportunity
7.5 Australia 2017 to 2023
7.5.1 Australia by Pathogen
7.5.2 Australia by Technology Opportunity
7.6 Remainder of Asia Pacific 2017 to 2023
7.6.1 Remainder of Asia Pacific by Pathogen
7.6.2 Remainder of Asia Pacific by Technology Opportunity

8. Country Markets – Latin America, Africa & The Middle East 2017 to 2023
8.1 Brazil 2017 to 2023
8.1.1 Brazil by Pathogen
8.1.2 Brazil by Technology Opportunity
8.2 Mexico 2017 to 2023
8.2.1 Mexico by Pathogen
8.2.2 Mexico by Technology Opportunity
8.3 Remainder of Latin America 2017 to 2023
8.3.1 Remainder of Latin America by Pathogen
8.3.2 Remainder of Latin America by Technology Opportunity
8.4 Africa & The Middle East 2017 to 2023
8.4.1 Africa & The Middle East by Pathogen
8.4.2 Africa & The Middle East by Technology Opportunity

9. Global Market Summary 2017 to 2023
9.1 Global Market Summary 2017 to 2023
9.1.1 Global Market Summary by Pathogen
9.1.2 Global Market Summary by Technology Opportunity

10. The Future of AMR

Appendices
I. United States Medicare System: Top Selling Drugs 2011-2015

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class
Table 2 USA - Outpatient Use of Antibiotics Top 5
Table 3  Market Players by Type
Table 4  Known Human Pathogenic Diseases
Table 5 The Key Market Opportunities
Table 6 - Market Potential DRSP Therapeutic
Table 7 - Market Potential DRC Therapeutic
Table 8 Eight Technologies under development
Table 9 Antibodies Approved for Infectious Disease Treatment
Table 10 Therapeutic Technology Research - # of Companies
Table 11  USA by Pathogen
Table 12  USA by Technology Opportunity
Table 13  Canada by Pathogen
Table 14  Canada by Technology Opportunity
Table 15  France By Pathogen
Table 16  France By Technology Opportunity
Table 17  Germany By Pathogen
Table 18  Germany By Technology Opportunity
Table 19  UK By Pathogen
Table 20  UK By Technology Opportunity
Table 21  Spain by Pathogen Table 22  Spain by Technology Opportunity
Table 23  Italy By Pathogen
Table 24  Italy By Technology Opportunity
Table 25  Russia By Pathogen
Table 26  Russia By Technology Opportunity
Table 27  Remainder of Europe and Former USSR By Pathogen
Table 28  Remainder of Europe and Former USSR By Technology Opportunity
Table 29  China By Pathogen
Table 30  China By Technology Opportunity
Table 31  Japan By Pathogen
Table 32  Japan By Technology Opportunity
Table 33  South Korea By Pathogen
Table 34  South Korea By Technology Opportunity
Table 35  India by Pathogen
Table 36  India by Technology Opportunity
Table 37  Australia By Pathogen
Table 38  Australia By Technology Opportunity
Table 39  Remainder of Asia Pacific By Pathogen
Table 40  Remainder of Asia Pacific By Technology Opportunity
Table 41  Brazil By Pathogen
Table 42  Brazil By Technology Opportunity
Table 43  Mexico By Pathogen
Table 44  Mexico By Technology Opportunity
Table 45  Remainder of Latin America By Pathogen
Table 46  Remainder of Latin America By Technology Opportunity
Table 47  Africa & The Middle East by Pathogen
Table 48  Africa & The Middle East by Technology Opportunity
Table 49  Global Market Summary by Pathogen
Table 50  Global Market Summary by Technology Opportunity
Table 51 2011 to 2015 Top Selling Drugs

Table of Figures

Figure 1 Pharmaceutical Spending History by Country
Figure 2 AMR and Antibiotic Introduction
Figure 3 The Death Toll of AMR
Figure 4 Phage T4 Anatomy and Infection Cycle

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ABAC Therapeutics
  • Abbvie
  • Absynth Biologics
  • Achaogen, Inc.
  • Achillion Pharmaceuticals
  • AiCuris
  • Alaxia SAS
  • Allecra Therapeutics
  • Allergan
  • Alopexx Vaccine LLC
  • AmpliPhi Biosciences
  • Antabio S.A.S
  • AntibioTx
  • Arsanis
  • AstraZeneca
  • Auspherix Ltd
  • Aviragen Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Bioaster
  • BioFilm Pharma
  • Biolytx Pharmaceuticals
  • Biosergen
  • BioVersys GmbH
  • C3J Therapeutics, Inc.
  • Centauri Therapeutics Ltd
  • Cipla
  • Combioxin SA
  • Contrafect Corporation
  • Da Volterra
  • Debiopharm International SA
  • Deinobiotics/Deinove
  • Demuris
  • Destiny Pharma plc
  • discuva
  • DSM Sinochem Pharmaceuticals
  • Eligo Bioscience
  • Enanta Pharmaceuticals, Inc.
  • Entasis Therapeutics
  • EpiBiome
  • Fedora Pharmaceuticals Inc.
  • Fixed Phage
  • Forge Therapeutics
  • Helperby Therapeutics Ltd
  • Hennepin Life Sciences
  • ImmunNovative Developments, S.L.
  • Innovation Pharmaceuticals
  • Integrated Biotherapeutics
  • Iterum Therapeutics Limited
  • Johnson & Johnson (Janssen)
  • Karveel Pharmaceuticals
  • KBP Biosciences
  • KYORIN Pharmaceutical Co.,Ltd.
  • Lumavita
  • MaaT Pharma
  • Macrolide Pharmaceuticals
  • Madam Therapeutics
  • Melinta Therapeutics
  • Merck
  • Merlion Pharmaceuticals
  • Micreos
  • MicuRx
  • Motif BioSciences, Inc / Motif Bio PLC
  • Mutabilis SAS
  • Nabriva Therapeutics
  • Neem Biotech Ltd
  • Nemesis Bioscience
  • Northern Antibiotics Oy (Ltd)
  • Nosopharm
  • NovaBiotics Ltd
  • Novartis
  • Paratek Pharmaceuticals
  • Pfizer
  • Phage Technologies S.A
  • Pherecydes Pharma
  • Phico Therapeutics Ltd
  • Polyphor Ltd
  • Priaxon
  • Procarta Biosystems
  • Prommune
  • QureTech Bio AB
  • RedHill Biopharma
  • Redx Pharma Plc/ Redx Anti Infectives Ltd.
  • SelectX Pharmaceuticals, Inc.
  • SetLance srl
  • SmartPhage
  • Spero Therapeutics
  • Symphogen
  • Synereca Pharmaceuticals
  • TaiGen Biotechnology Co., Ltd.
  • Tetraphase Pharmaceuticals
  • The Medicines Company
  • Theravance Biopharma
  • Ultupharma AB
  • Vaxdyn
  • VenatoRx Pharmaceuticals
  • Vibiosphen
  • Vivexia
  • Warp Drive Bio
  • Westway Health
  • Wockhardt Ltd.
  • Xellia Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll